Table 4 Adverse Events [n(%)].

From: Intercalating and maintenance gefitinib plus chemotherapy versus chemotherapy alone in selected advanced non-small cell lung cancer with unknown EGFR status

 

Arm A (N = 109)

Arm B (N = 110)

P value

Common adverse events (any grade)

  Leukopenia

87(79.8%)

89(80.9%)

0.8387

  Neutropenia

73(67.0%)

75(68.2%)

0.8484

  Thrombocytopenia

62(56.9%)

53(48.2%)

0.1974

  Anemia

76(69.7%)

71(64.5%)

0.4146

  Abnormal ALT

14(12.8%)

15(13.6%)

0.8627

  Abnormal plasma creatinine

14(12.8%)

10(9.1%)

0.3740

  Nausea

23(21.1%)

13(11.8%)

0.0638

  Vomiting

14(12.8%)

9(8.2%)

0.2605

  Diarrhea

9(8.3%)

1(0.9%)

0.0098

  Dermal and subcutaneous disease

9(8.3%)

1(0.9%)

0.0098

Adverse Events (Frequency of ≥10%*) of CTCAE grade > 3

  All AEs, n(%)

59(54.1%)

55(50.0%)

0.5409

  Leukopenia

17(15.6%)

26(23.6%)

0.1342

  Neutropenia

28(25.7%)

25(22.7%)

0.6090

  Anemia

15(13.8%)

9(8.2%)

0.1863

  Thrombocytopenia

41(37.6%)

26(23.6%)

0.0248

  1. NOTE: Arm A: gemcitabine + carboplatin + gefitinib; Arm B: gemcitabine + carboplatin. *Frequency >10%: authors only chose to report an CTCAE (grade > 3) if it occurs in > 10% of the population.
Back to article page